InvestorsHub Logo
Followers 0
Posts 186
Boards Moderated 0
Alias Born 10/25/2010

Re: sparkyone post# 39251

Wednesday, 03/04/2015 3:56:22 PM

Wednesday, March 04, 2015 3:56:22 PM

Post# of 45205
Delta 9 tetrahydrocannabol is the active ingredient responsible for the psychoactive effects of Cannabis. Cortext currently has dronabinol in trial for sleep apnea. Dronabinol is the generic equivalent of Marinol, approved by the FDA in 1985 for nausea and weight loss due to complications of AIDS treatment and chemotherapy. Marinol is currently marketed by Solvay Pharma. Simply put Delta 9=dronabinol=Marinol. All the same stuff. It's generic so no one pharma can own the molecule. They can license various uses, which Solvay does, and Cortex would like to do.
Many websites such as stockgumshoe.com and outsider's club hype small companies attempting to license Delta 9 for whatever ails you. They compare it to tylenol or any fill in the blanks blockbuster you can think of. Due to Marijuana's Schedule One Classification my guess is that the FDA will go slow on any expansion of Delta9/dronibinol/Marinol indications, and doctors will be very cautious with off label dispensation. As more states adopt medical/rec. use it will become less valuable to pharma rather than more.
These are my opinions. Perhaps gfp can weigh in and provide a more informed opinion.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RSPI News